'On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Sun Pharmaceuticals Industries has increased 10.46% to Rs 13675.46 crore. Operating profit margin has jumped from 28.08% to 29.32%, leading to 15.31% rise in operating profit to Rs 4,009.02 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 14.07% to 10.37%. Purchase of finished goods cost rose from 6.56% to 9.12%. Employee cost decreased from 19.45% to 18.79%. Other expenses rose from 31.31% to 32.20%.
Other income rose 86.10% to Rs 465.62 crore. PBIDT rose 20.06% to Rs 4474.64 crore. Provision for interest rose 48.32% to Rs 51.51 crore.
PBDT rose 19.79% to Rs 4423.13 crore. Provision for depreciation rose 1.35% to Rs 630.56 crore.
Profit...
Pleaselogin & subscribe to view the full report.
More Reports
-
(10-May-2025)
Dr Reddys Laboratories
NP surged 21.64%
-
(10-May-2025)
Bank of India
Healthy loan growth, other income jumps boosting bottom-line
-
(10-May-2025)
Voltas
Net jumps 107% driven by unitary cooling products
-
(10-May-2025)
K P R Mill
Revenue up 5.4% YoY to Rs 6387.9 cr in FY2025
|
|